Stock Analysis
Vaxcyte, Inc. (PCVX) Stock Analysis
Vaxcyte, Inc. (PCVX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Vaxcyte, Inc. (PCVX) currently has an AIQ Score of 66/100, indicating a bullish setup. Momentum is the strongest factor at 81/100. Risk is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PCVX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $63.37 |
| AIQ Score | 66/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $9.44B |
| P/E Ratio (TTM) | -7.85 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.99 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.26 |
| Volume | 623.63K |
| 52-week range | $42.40-$90.75 |
| RSI 14 | 49.5 |
| 50-Day SMA | $62.24 |
| 200-Day SMA | $57.70 |
| Analyst Price Target | $122.33 |
| Next Earnings | Feb 23, 2027 |
PCVXVaxcyte, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum81
- Value—
- Quality54
- Risk resilience53
- Sentiment—
PCVX Stock Analysis Summary
Vaxcyte, Inc. (PCVX) currently has an AIQ Score of 66/100, indicating a bullish setup. Momentum is the strongest factor at 81/100. Risk resilience is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, PCVX has AIQ Score of 66/100 with Momentum base of 81/100 and fading Risk resilience at 53/100. Wait for component alignment before adding exposure.
Momentum (81/100) leads while Risk resilience (53/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.04% stock move · PCVX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PCVX Bullish or Bearish Right Now?
PCVX currently has a bullish overall setup. Momentum is the strongest factor at 81/100, while Risk Resilience is weakest at 53/100. The current evidence suggests a constructive setup.
- - Momentum is constructive at 81/100.
- - Price is +1.82% above its 50-day SMA.
- - Analyst target implies +93.05% upside from the latest quote.
- - Technical consensus has more sell votes than buy votes (19 vs 17).
Current Consensus
PCVX's Technical Analysis Consensus is currently Neutral, with 17 buy, 10 neutral, and 19 sell votes. PCVX's 14-day RSI is 49.5, which places the stock in a neutral momentum range. PCVX's beta is 1.26, indicating greater market sensitivity than the broad market.
What Changed in PCVX?
The largest recent change in PCVX is Risk Resilience moving down by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the PCVX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PCVX Decision Framework
Public evidence layers, setup checks, and risk context for Vaxcyte, Inc..
Vaxcyte, Inc. (PCVX) Stock Analysis
Vaxcyte, Inc. has an AIQ Score of 66/100 in a Bullish regime. Momentum is strongest at 81/100. Beta is 1.26, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PCVX is in a Bullish AIQ regime with score 66/100. |
| Signal Conflict | The primary conflict is that momentum leads at 81/100 while risk lags at 53/100. |
| Factor Evidence | Momentum 81/100 · Quality 54/100 · Risk 53/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 81/100.
Momentum is 81/100 and RSI (14) is 49.5.
PCVX is in a Bullish regime at 66/100.
Risk factor is 53/100 with beta 1.26 and annual volatility 56.19%.
Current conflict: momentum leads at 81/100 while risk lags at 53/100.
PCVX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PCVX Fundamentals
PCVX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PCVX Technical Analysis
PCVX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PCVX Stock Catalysts
Track PCVX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PCVX Dividend Analysis
PCVX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PCVX Financial Data
PCVX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PCVX Risk Analysis
PCVX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PCVX Stock News
PCVX stock news, market tone, recent headlines, and catalyst context.
PCVX vs Biotechnology Peers
Current peer cohort: PCVX · PGEN · PRAX · PTGX · PVLA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PCVX Current stock | 66/100 | — | 81/100 | 53/100 | 0.79 | 56.19% | Current |
| PGEN Precigen, Inc. | 55/100 | 63/100 | 55/100 | 31/100 | 0.57 | 85.43% | PCVX vs PGEN |
| PRAX Praxis Precision Medicines, Inc. | 57/100 | — | 48/100 | 47/100 | 1.13 | 75.11% | PCVX vs PRAX |
| PTGX Protagonist Therapeutics, Inc. | 73/100 | 72/100 | 70/100 | 70/100 | 1.24 | 40.11% | PCVX vs PTGX |
| PVLA Palvella Therapeutics, Inc. | 70/100 | — | 84/100 | 47/100 | 1.12 | 84.47% | PCVX vs PVLA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for PCVX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PCVX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PCVX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PCVX Stock FAQ
What is PCVX stock price today?
Vaxcyte, Inc.'s current stock price is $63.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PCVX bullish or bearish right now?
PCVX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PCVX's market cap?
PCVX's market cap is $9.44B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PCVX's current P/E ratio?
PCVX's current P/E ratio is -7.85 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PCVX's RSI?
PCVX's 14-day RSI is 49.5 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PCVX above its 50-day and 200-day moving averages?
PCVX is 1.82% from its 50-day SMA and 9.82% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PCVX's next earnings date?
PCVX's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PCVX pay a dividend?
PCVX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.